Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: Findings from the veterans health administration

BMC Cardiovascular Disorders

Volumn 17, Issue 1, 2017, Pages

  Borne, Ryan T ^a   O'Donnell, Colin ^b   Turakhia, Mintu P ^c,d   Varosy, Paul D ^a,b   Jackevicius, Cynthia A ^e   Marzec, Lucas N ^a   Masoudi, Frederick A ^a   Hess, Paul L ^a,b   Maddox, Thomas M ^f   Ho, P Michael ^a,b  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atrial fibrillation; Direct oral anticoagulants; Medication adherence

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN; RIVAROXABAN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE;

AGED; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR DISEASE ASSESSMENT; CEREBROVASCULAR ACCIDENT; CHA2DS2 VASC SCORE; COHORT ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; UNITED STATES; BLOOD; BLOOD CLOTTING; COMPLICATION; DRUG EFFECTS; GOVERNMENT; MIDDLE AGED; MORTALITY; ODDS RATIO; ORAL DRUG ADMINISTRATION; PRESCRIPTION; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; VETERANS HEALTH;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BLOOD COAGULATION; DABIGATRAN; DRUG PRESCRIPTIONS; FACTOR XA INHIBITORS; FEMALE; HUMANS; LINEAR MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PROPORTIONAL HAZARDS MODELS; PYRAZOLES; PYRIDONES; RETROSPECTIVE STUDIES; RISK FACTORS; RIVAROXABAN; STROKE; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; VETERANS HEALTH;

EID: 85028645265     PISSN: None     EISSN: 14712261     Source Type: Journal    
DOI: 10.1186/s12872-017-0671-6     Document Type: Article

References (20)

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study. Circulation. 2014;129(8):837-47.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857.
3. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, TE RPAV, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12):1139.
4. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees and Investigators. Apixaban versus Warfarin in patients with Atrial fibrillation. N Engl J Med. 2011;365(11):981.
5. Patel MR, Mahaffrey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus Warfarin in Nonvalvular Atrial fibrillation. N Engl J Med. 2011;365(10):883.
6. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomized trials. Lancet. 2014;383(9921):955.
7. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119:3028-35.
8. Shore S, Carey EP, Turkhia MP, Jackevicius CA, Cunningham F, Pilote L, Bradley SM, Maddox TM, Grunwald GK, Baron AE, Rumsfeld JS, Varosy PD, Schneider PM, Marzec LN, Ho PM. Adherence to dabigatran therapy and longitudinal patient outcomes: insights from the veterans health administration. Am Heart J. 2014;167:810-7.
9. Gorst-Rasmussen A, Skjoth F, Larsen TB, Rasmussen LH, Lip GYH, Lane DA. Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nation wide cohort study. J Thromb Haemost. 2015;13(4):495-504.
10. Tsai K, Erickson SC, Yang J, Harada AS, Solow BK, Lew HC. Adherence, persistence, and switching patterns of dabigatran etexilate. Am J Manag Care. 2013;19(9):e325-32.
11. Schulman S, Shortt B, Robinson M, Eikelboom JW. Adherence to anticoagulant treatment with dabigatran in a real-world setting. J Thromb Haemost. 2013;11:1295-9.
12. Ho PM, Magid DJ, Shetterly SM, Olson KL, Maddox TM, Peterson PN, Masoudi FA, Rumsfeld JS. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J. 2008;155(4):772-229.
13. Mochari H, Ferris A, Adigopula S, Henry G, Mosca L. Cardiovascular disease knowledge, medication adherence, and barriers to preventative action in a minority population. Prev Cardiol. 2007;10(4):190-5.
14. Song X, Sander SD, Varker H, Amin A. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation. Am J Cardiovasc Drugs. 2012;12(4):245-53.
15. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-97.
16. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med. 2006;166:1863-41.
17. Rasmussen JN, Chong A, Alter DA. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA. 2007;297:177-86.
18. Spertus JA, Kettelkamp P, Vance C, Decker C, Jones PG, Rumsfeld JS, Messenger JC, Khanal S, Peterson ED, Bach RG, Krumholz HM, Cohen DJ. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry. Circulation. 2006;113:2803-9.
19. Hope CJ, Wu J, Tu W, Young J, Murray MD. Association of medication adherence, knowledge, and skills with emergency department visits by adults 50 years or older with congestive heart failure. Am J Health Syst Pharm. 2004;61:2043-9.
20. Hess LM, Raebel MA, Conner DA, et al. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. Ann Pharmachother. 2006;40:1280-8.